<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-05-15">15 May 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">S</forename><surname>Huhn</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Weinhold</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Myeloma Institute</orgName>
								<orgName type="institution">University of Arkansas for Medical Sciences</orgName>
								<address>
									<settlement>Little Rock</settlement>
									<region>AR</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Nickel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Pritsch</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Division of Biostatistics</orgName>
								<orgName type="institution">German Cancer Research Center</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Division of Biostatistics</orgName>
								<orgName type="institution">German Cancer Research Center</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">National Center for Tumor Diseases Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Huegle-Doerr</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Vogel</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Janssen-Cilag</orgName>
								<address>
									<settlement>Neuss</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Angermund</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution">Janssen-Cilag</orgName>
								<address>
									<settlement>Neuss</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Hänel</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution">Klinikum Chemnitz gGmbH</orgName>
								<address>
									<settlement>Chemnitz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Salwender</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Hematology/Oncology</orgName>
								<orgName type="institution">Asklepios Klinik Altona</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Weisel</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Internal Medicine II-Hematology and Oncology</orgName>
								<orgName type="institution">Eberhard-Karls-University Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Dürig</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">University Hospital Essen</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Görner</surname></persName>
							<affiliation key="aff9">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Community Hospital Bielefeld</orgName>
								<address>
									<settlement>Bielefeld</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Kirchner</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Medical Clinic III Hematology and Oncology</orgName>
								<orgName type="institution">Städt. Krankenhaus Siloah</orgName>
								<address>
									<settlement>Hannover</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Peter</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">2nd Medical Department</orgName>
								<orgName type="institution">Academic Teaching Hospital of the Charité</orgName>
								<address>
									<addrLine>Carl-Thiem-Klinikum Cottbus</addrLine>
									<settlement>Cottbus</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">U</forename><surname>Graeven</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Hematology, Oncology and Gastroenterology</orgName>
								<orgName type="institution">Maria-Hilf-Krankenhaus</orgName>
								<address>
									<settlement>Mönchengladbach</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Lordick</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">3rd Medical Department, Haematology and Oncology</orgName>
								<orgName type="institution">Klinikum Braunschweig</orgName>
								<address>
									<settlement>Braunschweig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="institution" key="instit1">University Cancer Center Leipzig (UCCL)</orgName>
								<orgName type="institution" key="instit2">University Medical Center Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Hoffmann</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution" key="instit1">Medical Clinic A</orgName>
								<orgName type="institution" key="instit2">Klinikum der Stadt Ludwigshafen gGmbH</orgName>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="institution">Ludwigshafen am Rhein</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Reimer</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Hematology, Oncology and Stem Cell Transplantation</orgName>
								<address>
									<addrLine>Evangelisches Krankenhaus Essen-Werden gGmbH</addrLine>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Blau</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Medical Clinic III Hematology and Oncology</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Jauch</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Institute of Human Genetics</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Dembowsky</surname></persName>
							<affiliation key="aff20">
								<orgName type="institution">Polyphor Ltd</orgName>
								<address>
									<settlement>Allschwil</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Möhler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="institution">inVentiv Health</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Wuchter</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Institute of Transfusion Medicine and Immunology</orgName>
								<orgName type="department" key="dep2">Medical Faculty Mannheim</orgName>
								<orgName type="institution" key="instit1">German Red Cross Blood Service Baden-Württemberg-Hessen</orgName>
								<orgName type="institution" key="instit2">Heidelberg University</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Internal Medicine V</orgName>
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">National Center for Tumor Diseases Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-05-15">15 May 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">8A9C70F7FF97F1B9C6126DE1D956BD59</idno>
					<idno type="DOI">10.1038/bmt.2017.91</idno>
					<note type="submission">Conceived and designed the study: SH, NW and HG; Performed the experiments</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>During the last 15 years, the outcome of patients with multiple myeloma (MM) has improved significantly as a result of therapy with novel drugs. <ref type="bibr" target="#b0">1</ref> Up to 75-90% of fit patients reach CR or very good partial response according to the IMWG criteria. <ref type="bibr" target="#b1">2</ref></s><s>3]<ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> Recently, the IMWG has acknowledged these results in the new consensus criteria for response assessment in MM, which now includes MRD diagnostics when patients have reached CR and MRD negativity as the deepest response. <ref type="bibr" target="#b1">2</ref></s><s>Along with the new consensus criteria, the IMWG pointed out that circulating tumor cells (CTCs) should be investigated for their value as a biomarker for response and prognosis since CTCs have been found in the PB of most patients at the time of diagnosis, and their level was identified as an independent prognostic factor. <ref type="bibr" target="#b1">2</ref> In this study, we performed a longitudinal quantitative analysis of CTCs and malignant plasma cells in the bone marrow (BM) in MM patients treated with novel agents and autologous stem cell transplantation (ASCT) using a highly sensitive ASO-PCR (⩽10 − 6 ).</s><s>We aimed to examine if CTCs could be used as a minimal invasive biomarker for response to therapy beyond MRD diagnostics that are usually performed when patients reach CR.</s><s>Samples were collected from patients who were treated within the open-label, randomized, multicenter phase III clinical trial MM5 for newly diagnosed MM patients of the German-speaking Myeloma Multicenter Group (GMMG, EudraCT no.</s><s>2010-019173-16), <ref type="bibr" target="#b5">6</ref> and who reached CR or suspected CR until spring 2014 (Table <ref type="table" target="#tab_0">1</ref>; N = 41; 104 PB; 29 BM).</s><s>BM samples were collected at diagnosis and at the time of CR or suspected CR (CR N = 18/29), and PB samples were collected at diagnosis and after the induction therapy (IT: PAd or VCD), ASCT and consolidation therapy (Cons.)</s><s>(CR N = 33/104; Table <ref type="table" target="#tab_0">1</ref>).</s><s>Additional 20 PB samples (at diagnoses and/or after IT, eight pairs) of 11 patients treated within the HOVON-65/GMMG- PB -Therapy cycle 0.61 7.47x10 -3 5.09x10 <ref type="bibr">-5</ref> Tumour load log10 HD4 Trial 7 were included to investigate differential impacts of the PAD/PAd regime (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Tumor cell quantification was performed by patient-specific ASO-PCR assays designed to detect 1 tumor cell in 330 000 mono-nuclear cells (MNCs) in one PCR reaction and by extreme limiting dilution until no more amplification could be detected in at least 10 replicates. <ref type="bibr" target="#b7">8</ref></s><s>The proportion of clonotypic cells in a sample was then calculated using the algorithm of 'extreme limiting dilution analysis'. <ref type="bibr" target="#b8">9</ref></s><s>For MRD-negative results (MRD − ), a minimum of 10 6 cell equivalents had to be tested without any positive amplification if this amount of material was available to reach a sensitivity for MRD − o1/10 6 .</s></p><p><s>Statistical analyses were carried out using the R package NADA <ref type="bibr" target="#b9">10</ref> for left-censored data (Kendall's tau correlation coefficient, Akritas-Theil-Sen nonparametric line and Turnbull estimate of intercept).</s><s>The Peto and Peto modification of the Gehan-Wilcoxon test was used for differences of the median tumor load. <ref type="bibr" target="#b9">10</ref></s><s>MRD − results were included as censored data, using the number of tested cells as individual censoring value for each sample.</s><s>The median could not be calculated for groups that contained 450% censored data; in this case, mean values are presented.</s><s>The data were analyzed for different risk strata according to International Staging System (ISS) <ref type="bibr" target="#b10">11</ref> and cytogenetics at the time of diagnosis. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref></s><s>As high-risk (HR) cytogenetic markers, we included amp(1q) (more than three copies), deletion del (17p13) and the translocation t(4;14). <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b12">13</ref></s><s>All other patients were defined as standard risk (SR).</s></p><p><s>Among all 104 measurements in PB samples, CTCs were detected in 54 (MRD + ; median 5.63 × 10 − 5 ), with the lowest detectable number of CTCs of 7.75 × 10 − 7 (after ASCT, CR).</s><s>The median sensitivity for samples without detectable CTCs (MRD − ) was 1.09× 10 − 6 with the study wide weakest sensitivity of 9.08 × 10 − 6 .</s></p><p><s>At the time of diagnosis, CTCs were detected in 24 of 26 patients (92%; median relative load in MRD + 3.76 × 10 − 4 ) with a maximum of 11% CTCs in PB MNCs.</s><s>After IT, the number of CTCs was reduced significantly by 97% and reduced by an additional 86% after ASCT (Diagnosis-IT mean: 7.10 × 10 − 3 vs 2.07 × 10 − 4 , P = 5.09 × 10 − 5 ; IT-ASCT mean: 2.07 × 10 − 4 vs 2.98 × 10 − 5 , P = 7.47 × 10 − 3 ; Figure <ref type="figure" target="#fig_1">1a</ref>; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>The most significant difference in CTCs was detected between the time of diagnosis and after ASCT (99.6% reduction; mean 7.1 × 10 − 3 vs 2.98 × 10 − 5 , P = 2.72 × 10 − 9 ).</s><s>Comparing the included Bortezomibbased ITs-PAd/PAD and VCD (Figure <ref type="figure" target="#fig_1">1c</ref>), we could neither detect significant differences in the magnitude of CTC reduction from diagnosis to IT (98% vs 96%), nor in the number of CTCs after IT in the PAd/PAD-and VCD-treated patients (median VCD: 1.14 × 10 − 5 ; median PAd/PAD: 1.83 × 10 − 6 ; P = 0.191; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Only 3 of 21 BM samples were MRD − (14.3%) in patients in CR (median sensitivity of MRD − 8.75 × 10 − 7 ).</s><s>The median relative tumor load in the MRD + patients was 1.56 × 10 − 5 (range 3.48 × 10 − 4 to 3.3 × 10 − 7 ; Figure <ref type="figure" target="#fig_1">1d</ref>; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>With PB samples collected irrespective of response, we could show that CTCs were not only reduced significantly with every cycle of therapy, but that this reduction also positively correlated with clinical response (tau = 0.41; P = 1.07 × 10 − 10 ; Figures <ref type="figure" target="#fig_1">1a and  b</ref>; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>Of note, in 8/19 patients in CR (42%), we detected CTCs (Figure <ref type="figure" target="#fig_1">1d</ref>).</s></p><p><s>Stratifying the data for risk according to cytogenetics, we found a significantly higher number of CTCs at the time of diagnosis in HR patients than in SR patients (median: 1.6 × 10 − 3 vs 1.1 × 10 − 4 , P = 0.005; Figure <ref type="figure" target="#fig_1">1e</ref>).</s><s>After IT, the number of CTCs was significantly reduced in HR patients (99.8% reduction) and SR patients (89% reduction) (HR median IT: 1.1 × 10 − 5 , P = 1.28 × 10 − 4 ; SR median IT: 5.35 × 10 − 6 , P = 0.04), and no significant difference after IT could be detected between the two risk groups (P = 0.95) (Figure <ref type="figure" target="#fig_1">1e</ref>; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Between the different ISS stages, no significant differences in the number of CTCs at the time of diagnosis and after ASCT were detected (Figure <ref type="figure" target="#fig_1">1f</ref>; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>However, while patients with ISS I and II already showed a significant reduction of CTCs from diagnosis to IT (ISS I 88.9% reduction, P = 0.01; and ISS II 99.5% reduction, P = 0.004, respectively) in ISS III patients, CTCs were only reduced by ASCT (99.97% reduction, P = 0.005) (Figure <ref type="figure" target="#fig_1">1f</ref>; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Comparing the tumor load in BM and PB, we found that in only 3/24 pairs, were both entities MRD − (12.5%; median sensitivity: BM 8.95 × 10 − 7 , PB 9.36 × 10 − 7 ).</s><s>In 16/24 pairs, BM was MRD + , while PB was MRD − (66.6%; median tumor load BM + 1.56 × 10 − 5 ; median sensitivity PB − 6.36 × 10 − 7 ).</s><s>In only 5/24 pairs, was PB MRD + , but most interestingly, all but one corresponding BM sample was MRD + .</s><s>Adding an additional eight BM/PB pairs collected after stem cell mobilization or during maintenance therapy, we could confirm that as long as PB is MRD + , BM is also MRD + (N = 14 PB + pairs; Figure <ref type="figure" target="#fig_1">1h</ref>; median BM + 6.3 × 10 − 5 ; median PB + 6.9 × 10 − 6 ; Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>Further analysis showed a strong correlation between tumor load in PB and BM if the paired PB sample was MRD + (tau = 0.604; P = 0.0031; Figure <ref type="figure" target="#fig_1">1g</ref>).</s><s>In the only PB + /BM − case, tumor load in PB was 7.75x10 − 7 and sensitivity of the BM measurement was 9.13 × 10 − 7 .</s></p><p><s>Taken together, our analysis showed both a significant correlation with the number of tumor cells in BM if PB was MRD + and a significant correlation of the number of CTCs with response to therapy.</s><s>Accordingly, CTCs could as such be a promising minimal invasive biomarker for the general activity of the disease in the BM.</s></p><p><s>In comparison to other recently published studies about MRD diagnostics in BM at CR, our rates of MRD − patients are low (14.3%).</s><s>This might be due to the fact our MRD assay reaches a sensitivity that is even below 10 − 6 .</s><s>3]<ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref> Nevertheless, by increased sensitivity, we were able to identify 43% more BM MRD + patients and 12% more PB MRD + patients at CR compared to MFC.</s><s>This highlights the fact that sensitivity is essential for MRD diagnostics in BM as well as for the analysis of CTCs.</s><s>We conclude that CTCs could serve as a surrogate for BM evaluations until PB is MRD − , but cannot stand alone for MRD detection.</s><s>Larger studies of CTCs in MM patients and the analysis of their effect on PFS and overall survival are needed to confirm and evaluate our findings.</s><s>Future developments in improvement of MRD assay sensitivity and applicability, potential automatization, high-throughput applications and cost reduction will determine which assay serves best for the clinical application of MRD diagnostics and CTC evaluation.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>(a) GMMG-MM5-correlation between tumor load in PB and therapy cycle; N = 106.</s><s>(b) GMMG-MM5-correlation between tumor load in PB and response to therapy.</s><s>(c) GMMG-MM5 and GMMG-HD4-tumor load in PB at diagnosis and after different Bortezomib-based induction therapy regimes.</s><s>PAd = bortezomib/doxorubicin/reduced dose dexamethasone (240 mL per cycle); VCD = bortezomib/cyclophosphamide/dexamethasone; PAD = bortezomib/doxorubicin/dexamethasone (480 mg per cycle).</s><s>(d) GMMG-MM5-tumor load in BM and PB at the time point at which the patients had reached CR (after IT, after ASCT and after Cons.).</s><s>(e) GMMG-MM5-correlation between tumor load in PB and therapy cycle, stratified for the presence or absence of high-risk cytogenetics (HR = amp(1q) more than three copies, deletion 17p13, t(4:14) and t(14:16); SR = low risk (all others)); HR = 1; SR = 0. (f) GMMG-MM5-correlation between tumor load in PB and therapy cycle, stratified for ISS Stage.</s><s>Ordinary boxplots ignoring censoring.</s><s>(g) GMMG-MM5-correlation between tumor load in BM and PB if PB is positive; N = 14 pairs.</s><s>(h) Tumor load in BM and PB if PB is positive; N = 14 pairs.</s></p></div></figDesc><graphic coords="2,96.53,63.05,391.94,560.66" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s><s>Continued.</s></p></div></figDesc><graphic coords="3,93.77,66.53,410.06,142.22" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>GMMG-MM5 and HOVON-65/GMMG-HD4 sample set</s></p></div></figDesc><table><row><cell></cell><cell>N Patients</cell><cell></cell><cell></cell><cell></cell><cell cols="5">N Samples-therapy regime per time point</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Diagnosis</cell><cell></cell><cell></cell><cell>IT</cell><cell></cell><cell></cell><cell>ASCT</cell><cell cols="2">Cons.</cell><cell>∑</cell></row><row><cell></cell><cell></cell><cell>PAd</cell><cell>VCD</cell><cell>PAD</cell><cell>PAd</cell><cell>VCD</cell><cell>PAD</cell><cell>PAd</cell><cell>VCD</cell><cell>PAd</cell><cell>VCD</cell><cell></cell></row><row><cell>GMMG-MM5 BM</cell><cell>23</cell><cell>0</cell><cell>0</cell><cell>-</cell><cell>2</cell><cell>3</cell><cell>-</cell><cell>8</cell><cell>8</cell><cell>4</cell><cell>4</cell><cell>2 9</cell></row><row><cell>GMMG-MM5 PB</cell><cell>41</cell><cell>11</cell><cell>15</cell><cell>-</cell><cell>11</cell><cell>10</cell><cell>-</cell><cell>13</cell><cell>16</cell><cell>15</cell><cell>13</cell><cell>104</cell></row><row><cell>GMMG-HD4 PB</cell><cell>11</cell><cell>-</cell><cell>-</cell><cell>10</cell><cell>-</cell><cell>-</cell><cell>10</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>20</cell></row><row><cell>GMMG-MM5 BM/PB pairs</cell><cell>18</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>2</cell><cell>3</cell><cell>-</cell><cell>5</cell><cell>8</cell><cell>2</cell><cell>4</cell><cell>2 4</cell></row><row><cell></cell><cell>N Patients</cell><cell></cell><cell></cell><cell cols="6">N Samples-response to therapy per therapy regime</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell cols="2">Diagnosis</cell><cell></cell><cell>PR</cell><cell></cell><cell cols="2">VGPR</cell><cell>CR</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>PAd</cell><cell></cell><cell>VCD</cell><cell></cell><cell>PAd</cell><cell>VCD</cell><cell>PAd</cell><cell>VCD</cell><cell>PAd</cell><cell>VCD</cell><cell></cell></row><row><cell>GMMG-MM5 BM</cell><cell>23</cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell><cell>2</cell><cell>1</cell><cell>3</cell><cell>5</cell><cell>9</cell><cell>9</cell><cell>2 9</cell></row><row><cell>GMMG-MM5 PB</cell><cell>41</cell><cell>11</cell><cell></cell><cell>15</cell><cell></cell><cell>6</cell><cell>9</cell><cell>16</cell><cell>14</cell><cell>17</cell><cell>16</cell><cell>104</cell></row><row><cell>GMMG-MM5 BM/PB pairs</cell><cell>18</cell><cell>-</cell><cell></cell><cell>-</cell><cell></cell><cell>2</cell><cell>1</cell><cell>2</cell><cell>5</cell><cell>5</cell><cell>9</cell><cell>2 4</cell></row><row><cell></cell><cell>N Patients</cell><cell></cell><cell></cell><cell cols="7">N Patients-clinical parameter at the time of diagnosis</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>PAd</cell><cell>VCD</cell><cell cols="2">PAD</cell><cell>HR</cell><cell cols="2">SR</cell><cell>ISS I</cell><cell>ISS II</cell><cell>ISS III</cell><cell></cell></row><row><cell>GMMG-MM5 PB</cell><cell>41</cell><cell>20</cell><cell>21</cell><cell>-</cell><cell></cell><cell>16</cell><cell cols="2">25</cell><cell>16</cell><cell>15</cell><cell>10</cell><cell></cell></row><row><cell>GMMG-HD4 PB</cell><cell>11</cell><cell>-</cell><cell>-</cell><cell cols="2">11</cell><cell>5</cell><cell>5</cell><cell></cell><cell>3</cell><cell>4</cell><cell>2</cell><cell></cell></row><row><cell cols="13">Abbreviations: ASCT = autologous stem cell transplantation; BM = bone marrow; Cons. = consolidation therapy; HR = gain 1q21 more than three</cell></row><row><cell cols="13">copies, deletion 17p13 and t(4:14); ISS = International Staging System; IT = induction therapy; PAd = bortezomib/doxorubicin/reduced dose dexamethasone</cell></row><row><cell cols="13">(240 mL per cycle); PAD = bortezomib/doxorubicin/dexamethasone (480 mg per cycle); SR = low risk (all others); VCD = bortezomib/cyclophosphamide/</cell></row></table><note><p><s>dexamethasone; VGPR = very good partial response.</s><s>Bone Marrow Transplantation (2017) 52, 1194-1198 www.nature.com/bmt</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>14,15CONFLICT OF INTEREST SH, NW, JN, MP, TH, MHu, UB, BH-D, MHä, JD, MG, HK, UG, MHo, PR, AJ, NP and KD declare no conflict of interest.</s><s>MV and RA are employees of Janssen and hold stock in Johnson &amp; Johnson; HJS-Celgene: honoraria, travel grants and Amgen: honoraria; KW-Honoraria and Advisory Board von Amgen, BMS, Celgene, Janssen, Novartis, Takeda; FL-advisory role: BioNTech, Bristol-Myers-Squibb, Eli Lilly, GANYMED Pharmaceuticals, Merck Sharp &amp; Dohme, Roche Pharma AG.</s><s>Lecture honoraria: Amgen, Astra Zeneca, Eli Lilly, Merck Sharp &amp; Dohme, Roche Pharma AG, Servier.</s><s>Research grant: Boehringer Ingelheim, Fresenius Biotech.</s><s>Travel grants: Amgen, Bayer, Merck Sharp &amp; Dohme, Roche Pharma AG, Taiho Pharmaceutical; IWB-scientific grants Jabssen-Cilag and Celgene.</s><s>TM is an employee of inVentiv Health; PW-Honoraria and membership on Advisory Boards of Sanofi-Aventis.</s><s>Membership on Advisory Boards and Travel Grants from Hexal AG; HG-research support (institutions): Celgene, Janssen, Chugai, Novartis, BMS; Advisory Boards (institutions): Janssen, Celgene, Novartis, Amgen Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, BMS.</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Bone Marrow Transplantation (2017) 1194 -1198</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© The Author(s) 2017Supplementary Information accompanies this paper on Bone Marrow Transplantation website (http://www.nature.com/bmt)</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p><s>We thank all involved technicians, assistants and laboratories for their excellent work, and are grateful for the support by participating patients and their families.</s><s>This study was supported by grants of Janssen-Cilag, Neuss Germany and the Dietmar Hopp Stiftung, Walldorf Germany.</s><s>The GMMG-MM5 Trial (EudraCT no.</s><s>2010-019173-16) is supported by grants from Janssen-Cilag, Celgene, Chugai and The Binding Site.</s><s>The HOVON-65/GMMG-HD4 trial (EudraCT no.</s><s>2004-000944-26) was supported by the Dutch Cancer Foundation, by the German Federal Ministry of Education and Research, and by a grant from Janssen-Cilag.</s><s>The GMMG also received grants for this trial by Novartis, Amgen, Chugai, Roche and the Tumorzentrum Heidelberg/ Mannheim.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dispenzieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Q</forename><surname>Lacy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Gertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">K</forename><surname>Buadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pandey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1122" to="1128" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Paiva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Durie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Landgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moreau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="e328" to="e346" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI</title>
		<author>
			<persName><forename type="first">H</forename><surname>Avet-Loiseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Corre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lauwers-Cances</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M-L</forename><surname>Chretien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Robillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Leleu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trial</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page">191</biblScope>
			<date type="published" when="2009">2009. 2015</date>
		</imprint>
	</monogr>
	<note>Blood</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Rawstron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Child</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>De Tute</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Gregory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Bell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2540" to="2547" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Minimal residual disease testing after stem cell transplantation for multiple myeloma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Sherrod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Mosse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Cornell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="2" to="12" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Mai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Durig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haenel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Blau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1721" to="1729" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Sonneveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Schmidt-Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Der Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Jarari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Salwender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2946" to="2955" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Cremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wallmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Goldschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Moos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="633" to="636" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Smyth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol Methods</title>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="page" from="70" to="78" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Nondetects and Data Analysis: Statistics for Censored Environmental Data</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Helsel</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2005">2005</date>
			<publisher>John Wiley and Sons</publisher>
			<pubPlace>Hoboken, NJ, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">International staging system for multiple myeloma</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Greipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">San</forename><surname>Miguel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Durie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Crowley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Barlogie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Blade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="3412" to="3420" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Neben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seckinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="1150" to="1157" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p</title>
		<author>
			<persName><forename type="first">K</forename><surname>Neben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Lokhorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jauch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Bertsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hielscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Der Holt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="940" to="948" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient</title>
		<author>
			<persName><forename type="first">O</forename><surname>Landgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Owen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytometry B Clin Cytom</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="14" to="20" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Minimal residual disease in multiple myeloma: bringing the bench to the bedside</title>
		<author>
			<persName><forename type="first">S</forename><surname>Mailankody</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Korde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lesokhin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lendvai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hassoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stetler-Stevenson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="286" to="295" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The images or other third party material in this article are included in the article&apos;s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material</title>
	</analytic>
	<monogr>
		<title level="m">This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License</title>
				<imprint/>
	</monogr>
	<note>To view a copy of this license, visit http://</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
